Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 10, 2014, Pages 6438-6446

  Zhen, Lei ^a   Fan, Desheng ^b   Yi, Xianghua ^b   Cao, Xinming ^a   Chen, Dong ^a   Wang, Liming ^a  

^a Shanghai Stomatological Disease Center   (China)

^b TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Curcumin; EGFR; Invasion; OSCC; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; METABOLISM; MOUTH TUMOR; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84912072675     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371: 1695-1709.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
4. Brusevold IJ, Aasrum M, Bryne M, Christoffersen T. Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt. J Oral Pathol Med 2012; 41: 547-58.
5. Nakata Y, Uzawa N, Takahashi K, Sumino J, Michikawa C, Sato H, Sonoda I, Ohyama Y, Okada N, Amagasa T. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Eur J Cancer 2011; 47: 2364-2372.
6. Dai W, Li Y, Zhou Q, Xu Z, Sun C, Tan X, Lu L. Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor. J Oral Pathol Med 2014; 43: 250-257.
7. Doumiati S, Haupt K, Rossi C. Autophosphorylation activation and inhibition by curcumin of the epidermal growth factor receptor reconstituted in liposomes. J Mol Recognit 2012; 25: 623-629
8. Lin MC, Huang MJ, Liu CH, Yang TL, Huang MC. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity. Oral Oncol 2014; 50: 478-484.
9. Aquino G, Pannone G, Santoro A, Liguori G, Franco R, Serpico R, Florio G, De Rosa A, Mattoni M, Cozza V, Botti G, Losito S, Longo F, Staibano S, Cuda G, Lo Muzio L, Sbordone C, Bufo P, Grimaldi A, Caraglia M, Di Domenico M. pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations. Cancer Biol Ther 2012; 13: 967-977.
10. Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012; 48: 10851089.
11. Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C. Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801). Oncology 2014; 87: 7-20.
12. Maseki S, Ijichi K, Nakanishi H, Hasegawa Y, Ogawa T, Murakami S. Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma. Mol Clin Oncol 2013; 1: 918-924.
13. Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? J Thorac Dis 2014; 6: 578-580.
14. Nechushtan H, Vainer G, Stainberg H, Salmon AY, Hamburger T, Peretz T. A phase 1/2 of a combination of Cetuximab and Taxane for "triple negative" breast cancer patients. Breast 2014; 23: 435-438.
15. Xu Y, Zhang J, Han J, Pan X, Cao Y, Guo H, Pan Y, An Y, Li X. Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of α1-antitrypsin in lung cancer. Mol Oncol 2012; 6: 405-417.
16. Zhu DJ, Chen XW, Wang JZ, Ju YL, Ou Yang MZ, Zhang WJ. Proteomic analysis identifies proteins associated with curcumin-enhancing efficacy of irinotecan-induced apoptosis of colorectal cancer LOVO cell. Int J Clin Exp Pathol 2013; 7: 1-15.
17. Lv ZD, Liu XP, Zhao WJ, Dong Q, Li FN, Wang HB, Kong B. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol 2014; 7: 2818-2824.
18. Choi HY, Lim JE, Hong JH. Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis 2010; 13: 343-349.
19. Hung CM, Su YH, Lin HY, Lin JN, Liu LC, Ho CT, Way TD. Demethoxycurcumin modulates prostate cancer cell proliferation via AMPK-induced down-regulation of HSP70 and EGFR. J Agric Food Chem 2012; 60: 8427-8434.
20. Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner N. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 2014; 33: 173-180.
21. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006; 25: 278-287.
22. Sun XD, Liu XE, Huang DS. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Rep 2012; 6: 1267-1270.
23. Armanious H, Gelebart P, Mackey J, Ma Y, Lai R. STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int J Clin Exp Pathol 2010; 3: 654-664.
24. Huang M, Miao ZH, Zhu H, Cai YJ, Lu W, Ding J. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther 2008; 7: 1440-1449.
25. Yang CL, Liu YY, Ma YG, Xue YX, Liu DG, Ren Y, Liu XB, Li Y, Li Z. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One 2012; 7: e37960.
26. Kang N, Wang MM, Wang YH, Zhang ZN, Cao HR, Lv YH, Yang Y, Fan PH, Qiu F, Gao XM. Tetrahydrocurcumin induces G2/M cell cycle arrest and apoptosis involving p38 MAPK activation in human breast cancer cells. Food Chem Toxicol 2014; 67: 193-200.
27. Shin HK, Kim J, Lee EJ, Kim SH. Inhibitory effect of curcumin on motility of human oral squamous carcinoma YD-10B cells via suppression of ERK and NF-kappaB activations. Phytother Res 2010; 24: 577-582.
28. Lee EJ, Whang JH, Jeon NK, Kim J. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Ann N Y Acad Sci 2007; 1095: 113-128.
29. Dudás J, Fullár A, Romani A, Pritz C, Kovalszky I, Hans Schartinger V, Mathias Sprinzl G, Riechelmann H. Curcumin targets fibroblast-tumor cell interactions in oral squamous cell carcinoma. Exp Cell Res 2013; 319: 800-809.
30. Nozaki S, Endo Y, Kawashiri S, Nakagawa K, Yamamoto E, Yonemura Y, Sasaki T. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol 1998; 34: 58-62.
31. Ahmad N, Kalka K, Mukhtar H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001; 20: 2314-2317.
32. Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 2002; 29: 45-54.
33. Tsien CI, Nyati MK, Ahsan A, Ramanand SG, Chepeha DB, Worden FP, Helman JI, D'Silva N, Bradford CR, Wolf GT, Lawrence TS, Eisbruch A. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head Neck 2013; 35: 1323-1330.
34. Brusevold IJ, Aasrum M, Bryne M, Christoffersen T. Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt. J Oral Pathol Med 2012; 41: 547-558.